The FDA has issued a complete response letter for rivoceranib plus camrelizumab as a first-line treatment for unresectable ...

There are three main types of ovarian cancer: epithelial, germ cell, and stromal. Learn about each type’s defining ...

The addition of concurrent cisplatin to adjuvant radiation therapy conferred no benefit to women with intermediate-risk, ...

Tubular carcinoma, treatable and slow-growing, has a good prognosis and often needs less aggressive treatment.

Researchers have discovered the likely origin of a deadly form of ovarian cancer, offering new hope for early detection and ...

An expert discusses how third line (3L) systemic therapy for metastatic renal cell carcinoma (mRCC) is guided by prior ...

Among patients with renal cell carcinoma, those with larger tumors may yield the most benefit from SBRT compared with other ...

Labour MP Josh Fenton-Glynn said he would ‘never not be sorry that I’ve written eulogies for my brother but never a best man ...

Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in intermediate-to-high risk, ...

Renal cell carcinoma highlights from ASCO GU 2025 include follow-up data from the CheckMate 9ER study, updated COSMIC-313 results, and promising early data on casdatifan, a new HIF-2 alpha inhibitor.

Ovarian cancer is the deadliest form of gynecologic cancer, taking the lives of more than 13,000 women in the U.S. each year.